Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an…
By P. Kwo, E. Lawitz, J. McCone, E. Schiff, J. Vierling, D. Pound, Mitchell N. Davis, J. Galati, S. Gordon, N. Ravendhran and 9 more. The Lancet, 2010
716 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/df34af28c05526908742bccd702516657de220e9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011, result): “A direct comparison of the lead-in and non-lead-in groups in the BOC phase 2 study, however, did not show a significant difference in SVR rates for either the 28 week regimen, 56% and 54%, or the 48 week regimen, 75% and 67%, treated with and without lead-in, respectively.(11) Combining data across ”
- Telaprevir for retreatment of HCV infection. (2011, neutral): “Any adverse event 39 (15) 29 (11) 4 (3)”